QPPV.COM KNOWLEDGE ASSESSMENT

Ruxolitinib: Discovery, Development, Safety and Pharmacovigilance

Test your understanding of the concepts covered by Ruxolitinib: Discovery, Development, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A patient with PV develops squamous-cell carcinoma after long-term ruxolitinib and previous hydroxyurea. Which information is most useful for an individual and aggregate safety assessment?
Question 2 of 10 Why should a safety report specify whether the patient received immediate-release Jakafi or extended-release Jakafi XR?
Question 3 of 10 What is the best interpretation of EU authorisation for GvHD in younger children when the original pivotal trials enrolled older patients?
Question 4 of 10 A spontaneous-report database shows a disproportionate number of infections among ruxolitinib reports. What is the most appropriate next step?
Question 5 of 10 What is the most appropriate conclusion from the early phase I/II myelofibrosis programme described in the article?
Question 6 of 10 Which explanation best connects ruxolitinib's potential therapeutic effects with its important safety risks?
Question 7 of 10 Which statement best distinguishes public product-label listedness from causality assessment and company-core expectedness?
Question 8 of 10 A report of RESPONSE trial results gives only the 20.9% versus 0.9% composite primary endpoint. What is the most useful interpretive caveat?
Question 9 of 10 What is the significance of the assessed US label explicitly describing herpes simplex virus reactivation or dissemination in its postmarketing section?
Question 10 of 10 A team is drafting a dose-modification procedure for ruxolitinib and plans to use one cytopenia threshold table for myelofibrosis and GvHD. What is the main concern?

Select an answer to continue.

QPPV.com